Houston company's sustainable oil product reaches milestone production capacity 5 years early

overachieving

Thanks to technology advancements, Cemvita is now capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. Photo via cemvita.com

Houston-based biotech company Cemvita has achieved a key production goal five years ahead of schedule.

Thanks to technology advancements, Cemvita is now capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita has quadrupled output at the Houston plant. The company had planned to reach this milestone in 2029.

Cemvita, founded in 2017, says this achievement paves the way for increased production capacity, improved operational efficiency, and an elevated advantage in the sustainable oil market.

“What’s so amazing about synthetic biology is that humans are just scratching the surface of what’s possible,” says Moji Karimi, co-founder and CEO of Cemvita. “Our focus on the first principles has allowed us to design and create new biotech more cheaply and faster than ever before.”

The production achievement follows Cemvita’s recent breakthrough in development of a solvent-free extraction bioprocess.

In 2023, United Airlines agreed to buy up to one billion gallons of sustainable aviation fuel from Cemvita’s first full-scale plant over the course of 20 years.

Cemvita’s investors include the UAV Sustainable Flight Fund, an investment arm of Chicago-based United; Oxy Low Carbon Ventures, an investment arm of Houston-based energy company Occidental Petroleum; and Japanese equipment and machinery manufacturer Mitsubishi Heavy Industries.

From Your Site Articles
Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston biotech company expands leadership as it commercializes sustainable products

joining the team

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos.

Parachin will lead the Cemvita team that’s developing technology for production of bio-manufactured oil.

“It’s a fantastic moment, as we’re poised to take our prototyping to the next level, and all under the innovative direction of our co-founder Tara Karimi,” Parachin says in a news release. “We will be bringing something truly remarkable to market and ensuring it’s cost-effective.”

Moji Karimi, co-founder and CEO of Cemvita, says the hiring of Parachin represents “the natural next step” toward commercializing the startup’s carbon-to-oil process.

“Her background prepared her to bring the best out of the scientists at the inflection point of commercialization — really bringing things to life,” says Moji Karimi, Tara’s brother.

Parachin joins Garcia on Cemvita’s executive team.

Before being promoted to vice president of commercialization, Garcia was the startup’s commercial director and business development manager. He has a background in engineering and business development.

Founded in 2017, Cemvita recently announced a breakthrough that enables production of large quantities of oil derived from carbon waste.

In 2023, United Airlines agreed to buy up to one billion gallons of sustainable aviation fuel from Cemvita’s first full-scale plant over the course of 20 years.

Cemvita’s investors include the UAV Sustainable Flight Fund, an investment arm of Chicago-based United; Oxy Low Carbon Ventures, an investment arm of Houston-based energy company Occidental Petroleum; and Japanese equipment and machinery manufacturer Mitsubishi Heavy Industries.

------

This article originally ran on EnergyCapital.

Cemvita reported a successful pilot program on its gold hydrogen project in the Permian Basin. Photo courtesy of Cemvita

Houston cleantech company sees shining success with gold hydrogen

bling, bling

Houston-based cleantech startup Cemvita Factory is kicking things into high gear with its Gold Hydrogen product.

After successfully completing a pilot test of Gold Hydrogen in the oil-rich Permian Basin of West Texas, Cemvita has raised an undisclosed amount of funding through its new Gold H2 LLC spin-out. The lead investors are Georgia-based equipment manufacturer Chart Industries and 8090 Industries, an investment consortium with offices in New York City and Los Angeles.

Gold Hydrogen provides carbon-neutral hydrogen obtained from depleted oil and gas wells. This is achieved through bioengineering subsurface microbes in the wells to consume carbon and generate clean hydrogen.

Cemvita says it set up Gold H2 to commercialize the business via licensing, joint ventures, and outright ownership of hydrogen assets.

“We have incredible conviction in next-generation clean hydrogen production methods that leverage the vast and sprawling existing infrastructure and know-how of the oil and gas industry,” Rayyan Islam, co-founder and general partner of 8090 Industries, says in a news release.

Traditional methods of producing hydrogen without greenhouse gas emissions include electrolysis powered by renewable sources like wind, solar or water, according to Cemvita. However, production of green hydrogen through normal avenues eats up a lot of energy and money, the startup says.

By contrast, Cemvita relies on depleted oil and gas wells to cheaply produce carbon-free hydrogen.

“The commercialization and economics of the hydrogen economy will require technologies that produce the hydrogen molecule at a meaningful scale with no carbon emissions. Gold H2 is leading the charge … ,” says Jill Evanko, president and CEO of Chart Industries.

Investors in Cemvita include Oxy Low Carbon Ventures, an investment arm of Houston-based Occidental Petroleum, as well as BHP Group, Mitsubishi, and United Airlines Ventures.

Oxy Low Carbon Ventures and United Airlines Ventures are financing Cemvita’s work on sustainable jet fuel. United Airlines operates a hub at George Bush Intercontinental Airport Houston.

Founded by brother-and-sister team Moji and Tara Karimi in 2017, Cemvita uses synthetic biology to turn carbon dioxide into chemicals and alternative fuels.

The United and Occidental investment arms are planning to form a joint venture to commercialize the technology. Photo courtesy of Cemvita

Houston biotech startup scores $5M to fuel sustainable aviation innovation

seeing green

Houston cleantech startup Cemvita Factory has scored a $5 million investment from United Airlines Ventures, the venture capital fund of the Chicago-based airline.

The equity investment is aimed at propelling commercialization of sustainable aviation fuel through a process involving carbon dioxide (CO2) and synthetic microbes.

Oxy Low Carbon Ventures, a subsidiary of Houston-based Occidental Petroleum that’s a founding investor in Cemvita, and United Airlines Ventures are financing the startup’s work on sustainable jet fuel. United Airlines operates a hub at George Bush Intercontinental/Houston Airport.

If that work pans out, the United and Occidental investment arms plan to form a joint venture to commercialize the technology. The joint venture might include construction of plants for the production of sustainable aviation fuel.

Sustainable aviation fuel, known as SAF, is an alternative to jet fuel that uses non-petroleum feedstock and offers lower greenhouse gas emissions.

Founded by brother-sister team Moji and Tara Karimi in 2017, Cemvita Factory relies on synthetic biology to turn carbon dioxide into chemicals and alternative fuels, including SAF. The startup, founded in 2017, is among the first companies to employ this technology to support heavy-industry decarbonization and find ways to take advantage of microbiology to convert CO2 into fuel.

“The use of SAF is a promising approach that we believe can significantly reduce global emissions from aviation and further decarbonization initiatives to combat climate change,” Richard Jackson, president of operations for U.S. onshore resources and carbon management at Occidental, says in a news release.

Cemvita is the third SAF-related startup to receive an investment from United Airlines Ventures.

The partnership among Cemvita, Occidental, and United is among many initiatives seeking to ramp up production of SAF. For instance, the U.S. Department of Energy is collaborating with the U.S. Department of Transportation, the U.S. Department of Agriculture, and other federal agencies to develop a strategy for scaling SAF technology.

The global SAF market is projected to grow from $219 million in 2021 to more than $15.7 billion by 2030, according to Research and Markets.

The International Air Transport Association says more than 370,000 flights have been fueled by SAF since 2016. Over 26.4 million gallons of SAF were produced last year.

Last month in France, aircraft manufacturer Airbus flew a A380 test jet for about three hours with one of the four engines operating solely on SAF. The three other engines ran on conventional fuel.

In December 2021, United flew a 737 MAX 8 jet from Chicago O’Hare International Airport to Washington Reagan National Airport outside Washington, D.C., with one of the two engines operating only on SAF. It was the first commercial flight with passengers aboard to use SAF in that capacity. The other engine ran on conventional fuel.

United CEO Scott Kirby, who was aboard the historic flight, said the flight was “not only a significant milestone for efforts to decarbonize our industry, but when combined with the surge in industry commitments to produce and purchase alternative fuels, we’re demonstrating the scalable and impactful way companies can join together and play a role in addressing the biggest challenge of our lifetimes.”

For now, airlines are allowed to use up SAF for up to 50 percent of the fuel on commercial flights.

The brother-sister team at Houston-based Cemvita Factory is celebrating its series A initial closing. Photo courtesy of Cemvita

Houston-based carbon negative biotech startup closes series A round

money moves

A promising Houston startup using biotechnology to reduce carbon emissions is celebrating the initial closing of its series A fundraising round.

Cemvita Factory announced the news of its round closing, but didn't disclose the amount raised. 8090 Partners, a new investment group of entrepreneurs turned investors, led the round. Existing investor Oxy Low Carbon Ventures also contributed, along with Seldor Capital, Climate Capital, and others.

Founded by brother-sister team Moji and Tara Karimi in 2017, the company's technology biomimics photosynthesis to take carbon dioxide and turn it into something else. Cemvita uses this synthetic biology to decarbonize heavy industry across chemical manufacturing, mining, and oil and gas.

"Decarbonizing heavy industry is one of the most critical challenges in addressing climate change," says Moji Karimi, who serves as CEO, in a news release. "Synthetic biology is now primed to revolutionize heavy industries because of its inherent low-carbon advantages, and Cemvita is taking the lead in identifying and derisking the key applications."

Cemvita is currently working. with a number of clients — including Oxy, which announced its pilot in April — to reduce their carbon footprints.

"We believe the adoption rate and market size growth of our target applications will only accelerate due to the urgency for a low-carbon energy transition," Karimi continues. "The future of manufacturing will be low-carbon biomanufacturing and the future of mining will be sustainable biomining."

According to the release, the fresh funds will go toward launching Cemvita's bio-hydrogen solution, as well as to support construction and operation of a bio-ethylene pilot plant with Oxy. The pilot project, which reported success in the lab, is expected to scale.

"While synthetic biology has proven to be effective in re-imagining food and proteins, we've long held a firm belief in synthetic biology's promise in the heavy industrial space, but have waited until we've seen the right technology and team to drive real innovation in the sector," says Rayyan Islam, partner at 8090 Partners, in the release. "Cemvita's technology is a fundamental game-changer that provides a real economic solution and major players across heavy industry have taken serious notice."

It's not just investors and industrial players who have taken notice. Cemvita won the recent GS Beyond Energy Innovation Challenge from Cleantech.org. The company was also selected as a cohort member at Carbon2Value Initiative.

"Cemvita's technology is truly revolutionary in its use of CO2 and as a resource to provide viable economic solutions as more and more companies seek ways to reduce their carbon footprint. We remain impressed and excited about Cemvita's technology's positive impact on Earth and beyond," says Sidney N. Nakahodo, founder and general partner of Seldor Capital, in the release.

Cemvita Factory is working on a pilot plant with Oxy to scale its biotechnology. Photo via OxyLowCarbon.com

Oxy taps Houston startup's carbon negative biotechnology for new pilot plant

sustainability moves

Occidental's venture arm — Oxy Low Carbon Ventures — has announced its plans to construct and operate a one metric ton per month bio-ethylene pilot plant featuring Houston-based Cemvita Factory's technology that biomimics photosynthesis to convert carbon dioxide into feedstocks.

The new plant will scale the process, which was jointly developed between Cemvita and OLCV, and is expected sometime next year, according to a press release from Oxy.

"Today bio-ethylene is made from bio-ethanol, which is made from sugarcane, which in turn was created by photosynthesizing CO2. Our bio-synthetic process simply requires CO2, water and light to produce bio-ethylene, and that's why it saves a lot of cost and carbon emissions," says Moji Karimi, co-founder and CEO of Cemvita Factory, in the release. "This project is a great example of how Cemvita is applying industrial-strength synthetic biology to help our clients lower their carbon footprint while creating new revenue streams."

Oxy and Cemvita have been working together for a while, and in 2019, OLCV invested an undisclosed amount into the startup. The investment, according to the release, was made to jointly explore how these advances in synthetic biology can be used for sustainability efforts in the bio-manufacturing of OxyChem's products.

"This technology could provide an opportunity to offer a new, non-hydrocarbon-sourced ethylene product to the market, reducing carbon emissions, and in the future benefit our affiliate, OxyChem, which is a large producer and consumer of ethylene in its chlorovinyls business," says Robert Zeller, vice president of technology at OLCV, in a news release.

Moji Karimi founded the company with his sister and Cemvita CTO, Tara, in 2017. The idea was to biomimic photosynthesis to take CO2 and turn it into something else. The first iteration of the technology turned CO2 into sugar — the classic photosynthesis process. Karimi says the idea was to create this process for space, so that astronauts can turn the CO2 they breathe out into a calorie source.

"Nature provided the inspiration," noted Dr. Tara Karimi, co-founder and CTO of Cemvita Factory. "We took a gene from a banana and genetically engineered it into our CO2-utilizing host microorganism. We are now significantly increasing its productivity with the goal to achieve commercial metrics that we have defined alongside OLCV."

A couple weeks ago, Moji Karimi joined the Houston Innovators Podcast to discuss growth and challenges Cemvita Factory faced.

"We're defining this new category for application of synthetic biology in heavy industries for decarbonization," he shares on the show. Stream the episode below.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Axiom Space taps solar array developer for first space station module

space contract

Houston-based Axiom Space is making progress on developing its commercial space station.

The company awarded Florida-based Redwire Corporation a contract to develop and deliver roll-out solar array (ROSA) wings to power the Axiom Payload Power Thermal Module (AxPPTM), which will be the first module for the new space station.

AxPPTM will initially attach to the International Space Station. AxPPTM will later separate from the ISS and rendezvous with Axiom’s Habitat 1 (AxH1) on orbit. Eventually, an airlock, Habitat 2 (AxH2) and finally the Research and Manufacturing Facility (AxRMF) will be added to the first two Axiom modules.

AxPPTM is anticipated to launch toward the end of 2027. The two-module station (AxPPTM and AxH1) is expected to be operational as a free-flying station by 2028, and the full four-module station around 2030.

The modules will be integrated and assembled at Axiom Space’s Assembly and Integration facility, making them the first human-rated spacecraft built in Houston.

Redwire’s ROSA technology was originally developed for the ISS, according to Space News. It has yielded a 100 percent success rate on on-orbit performance. The technology has also been used on NASA’s Double Asteroid Redirection Test mission, the Maxar-built Power and Propulsion Element for the Artemis Lunar Gateway and Thales Alenia Space’s Space Inspire satellites.

“As a market leader for space power solutions, Redwire is proud to be selected as a strategic supplier to deliver ROSAs for Axiom Space’s first space station module,” Mike Gold, Redwire president of civil and international space, said in a news release. “As NASA and industry take the next steps to build out commercial space stations to maintain U.S. leadership in low-Earth orbit, Redwire continues to be the partner of choice, enabling critical capabilities to ensure on-orbit success.”

Greentown Houston to add new AI lab for energy startups

AI partnership

Greentown Labs has partnered with Shoreless to launch an AI lab within its Houston climatetech incubator.

"Climatetech and energy startups are transforming industries, and AI is a critical tool in that journey," Lawson Gow, Greentown's Head of Houston, said in a news release. "We're excited to bring this new offering to our entrepreneurs and corporate partners to enhance the way they think about reducing costs and emissions across the value chain."

Shoreless, a Houston-based company that enables AI adoption for enterprise systems, will support startups developing solutions for supply-chain optimization and decarbonization. They will offer Greentown members climate sprint sessions that will deliver AI-driven insights to assist companies in reducing Scope 3 emissions, driving new revenue streams and lowering expenses. Additionally, the lab will help companies test their ideas before attempting to scale them globally.

"The future of climatetech is intertwined with the future of AI," Ken Myers, Founder and CEO of Shoreless, said in a news release. "By launching this AI lab with Greentown Labs, we are creating a collaborative ecosystem where innovation can flourish. Our agentic AI is designed to help companies make a real difference, and we are excited to see the groundbreaking solutions that will emerge from this partnership."

Greentown and Shoreless will collaborate on workshops that address industry needs for technical teams, and Shoreless will also work to provide engagement opportunities and tailored workshops for Greentown’s startups and residents. Interested companies can inquire here.

Recently, Greentown Labs also partnered with Los Angeles-based software development firm Nominal to launch the new Industrial Center of Excellence at Greentown's Houston incubator. It also announced a partnership with Houston-based EnergyTech Nexus, which will also open an investor lounge on-site last month. Read more here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston medical institutions launch $6M kidney research incubator

NIH funding

Institutions within Houston’s Texas Medical Center have launched the Houston Area Incubator for Kidney, Urologic and Hematologic Research Training (HAI-KUH) program. The incubator will be backed by $6.25 million over five years from the National Institutes of Health and aims to create a training pipeline for researchers.

HAI-KUH will include 58 investigators from Baylor College of Medicine, Texas Children’s Hospital, the University of Texas Health Science Center at Houston, University of Houston, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University and Texas A&M University Institute of Biosciences and Technology. The program will fund six predoctoral students and six postdoctoral associates. Trainees will receive support in scientific research, professional development and networking.

According to the organizations, Houston has a high burden of kidney diseases, hypertension, sickle cell disease and other nonmalignant hematologic conditions. HAI-KUH will work to improve the health of patients by building a strong scientific workforce that leverages the team's biomedical research resources to develop research skills of students and trainees and prepare them for sustained and impactful careers. The funding comes through the National Institute of Diabetes and Digestive and Kidney Diseases.

The principal investigators of the project include Dr. Alison Bertuch, professor of pediatric oncology and molecular and human genetics at BCM; Peter Doris, professor and director of the Institute of Molecular Medicine Center for Human Genetics at UT Health; and Margaret Goodell, professor and chair of the Department of Molecular and Cellular Biology at Baylor.

“This new award provides unique collaborative training experiences that extend beyond the outstanding kidney, urology, and hematology research going on in the Texas Medical Center,” Doris said in a news release. “In conceiving this award, the National Institute of Diabetes and Digestive and Kidney Diseases envisioned trainee development across the full spectrum of skills required for professional success.”

Jeffrey Rimer, a professor of Chemical Engineering, is a core investigator on the project and program director at UH. Rimer is known for his breakthroughs in using innovative methods in control crystals to help treat malaria and kidney stones. Other co-investigators include Dr. Wolfgang Winkelmeyer (Baylor), Oleh Pochynyuk (UTHealth), Dr. Rose Khavari (Houston Methodist) and Pamela Wenzel (UT Health).

“This new NIH-sponsored training program will enable us to recruit talented students and postdocs to work on these challenging areas of research,” Rimer added in a release.

View All Listings